Patients who reported a pain flare experienced an almost 3-point greater current NPRS than those not reporting a flare (mean difference [SD] 2.70 [0.11]; p < 0.0001).
That is, at any time during follow-up, patients who reported a flare experienced an approximate 3-point increase in pain intensity (on a 0-10 scase) as compared to those who did not experience a flare.
Physicians' and nurses' estimates of the annual incidence of flares experienced by a patient with UC were lower than the patient-reported number of UC flares.
To evaluate long-term and dose response effects of the occurrence of a flare, patients were categorized according to the number of flares experienced during follow-up (none, 1, 2, or ≥3 flares for each definition of flare).
However, UK nurse estimates of flares experienced per year were higher than UK physician estimates for each severity grade (mild, 1.6 vs 0.9; moderate 3.4 vs 2.4; severe, 6.4 vs 4.4).
Respondents were categorized into mutually-exclusive groups based on number of gout flares experienced in the past 12 months (0/don't recall, 1 2, 3, 4 5, 6+), current presence of tophi (none, 1+, or not sure), and sUA level awareness (yes, no).
sUA level was positively correlated with flares experienced in the last 12 months, r s = 0.36, as well as the number of tophi currently present, r s = 0.37, both p < 0.001.
At clinic visits prior to each infusion and at follow-up, the following were performed: a count of tenderness and swelling of 68 joints; the number of flares experienced by patients or assessed by study personnel were recorded; patient and physician global assessment were assessed on a visual activity scale; and functional status was assessed by Health Assessment Questionnaire HAQQ).
This model is equivalent to a person with a long period of solar flare forecasting experience.
The company's latest offering is the Avaya Flare user experience that can be used with an optional desktop video device.
